Table 1: Baseline characteristics of the 124 Type 2 diabetes patients included, compared to 377 patients, who did not consent to CGM.

 

 

Patients included

N = 124

Patients that did not consent to CGM N = 377

Age

58 (11)

61 (12)*

Sex (% female)

46 %

38%

Ethnicity (% caucasian)

90 %

85%

BMI

32 (6)

31 (6)

HbA1c (mmol/mol)

58 (18)

58 (14)

Duration of DM (years)

11 (8)

13 (10)*

Blood pressure (MAP in mmHg)

98 (10)

97 (12)

Current smoking

20 %

16%

Use of antidepressant drugs

6%

9%

Complications

 

 

- microvascular

 

 

- neuropathy

26 %

30%

- retinopathy

20 %

25%

- nephropathy

19 %

20%

- macrovascular

32 %

38%

Therapy

 

 

-               None

5 %

5%

-               Oral agents only/ GLP-1 analoga

40 %

39%

-               Insulin

55 %

56%

o        Long-acting

6 %

6%

o        Premix

4 %

8%

o        Intensive

38 %

35%

o        CSII

7 %

7%

Glycaemic variability (SD)

2.2 (1.0)

Not determined

Questionnaires

 

 

PAID

12.5 (0-75)

7.5 (0-67.5)*

SF-12

Physical component score

Mental component score

 

39 (11)

46 (10)

 

41 (11)

48 (10)*

EQ5D

VAS score

Index Value

 

64 (18)

0.78 (-0.13 1.00)

 

65 (19)

0.81 (-0.26 - 1.00)

 

Results are described as mean (SD) or median (range) or percentage

HbA1c 58 mmol/mol equals 7.5%

Neuropathy is defined as a score on the neurothesiometer of > 25 V

Retinopathy is defined as any degree of retinopathy (as assessed by fundus photographs)

Nephropathy is defined as GFR (MDRD) < 60

Macro-vascular complication is defined as a composite endpoint (MI or CVA or angioplasty or vascular surgery (coronary, carotid, femoral, iliacal, aortal)

Antidepressants drugs were defined as drugs that are indicated for depression, however drugs commonly prescribed for neuropathic pain were excluded (amitriptyline, duloxetine, nortrilen)

*Significant difference (p < 0.05)